Abstract 12344: Suboptimal Control of Lipid Levels: Results From 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolemia (CEPHEUS)
Background: Five multicentre, cross-sectional Centralized Pan-regional Surveys on the Undertreatment of Hypercholesterolemia (CEPHEUS) were conducted in 29 countries across Asia, Western Europe, Eastern Europe, the Middle East and South Africa. The surveys assessed the current use and efficacy of lipid-lowering drugs (LLDs) worldwide and identified possible patient and physician characteristics associated with failure to achieve low-density lipoprotein cholesterol (LDL-C) targets. The aim of this analysis was to consolidate the global results from these surveys.*
Methods: The surveys involved patients aged 18 years or older who had been prescribed LLDs for at least 3 months (without dose changes for at least 6 weeks). A single visit was scheduled for data collection, including fasting plasma lipid and glucose levels. Cardiovascular risk profile and LDL-C goal attainment were assessed according to the 2004 updated US National Cholesterol Education Program Adult Treatment Panel III guidelines.
Results: A total of 33 198 patients were included in the final analysis; 55.0% were men and 90.9% had been prescribed statin monotherapy. Mean age was 60.2 years. Overall, only 50.5% of patients reached their target LDL-C level; the proportions were 62.8% (11 360/18 095) and 33.5% (4140/12 371) for patients being treated for primary and secondary cardiovascular prevention, respectively. LDL-C goals were attained in 74.4% (4729/6352), 57.0% (5291/9277) and 25.5% (3563/13 989) of patients at moderate/moderately high, high and very high CV risk, respectively (Figure).
Conclusions: LDL-C goal achievement in patients taking LLDs is suboptimal worldwide. More efforts are required to achieve therapeutic goals, particularly in patients at high and very high cardiovascular risk.
Reference: *http://clinicaltrials.gov/ct2/results?term=cepheus&Search=Search, accessed on 27 May 2014.
Author Disclosures: C. Chiang: Honoraria; Modest; AstraZeneca, Bayer, Boerhinger Ingelheim, Chugai, Daiichi Sankyo, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Tanabe, Takeda, TTY Biopharm. Consultant/Advisory Board; Modest; AstraZeneca, Merck Sharp & Dohme. J. Ferrières: Honoraria; Modest; Amgen, AstraZeneca, Merck Sharpe & Dohme, Sanofi-Aventis, Servier. N.N. Gotcheva: None. F.J. Raal: Research Grant; Modest; Amgen, Regeneron/Sanofi-Aventis. Speakers Bureau; Modest; Amgen, AstraZeneca, Pfizer, Regeneron/Sanofi-Aventis. Honoraria; Modest; Amgen, AstraZeneca, Regeneron/Sanofi-Aventis. Consultant/Advisory Board; Modest; Amgen, AstraZeneca, Regeneron/Sanofi-Aventis. A. Shehab: None. J. Sung: Research Grant; Modest; Kuhnil Pharmaceutical, Genzyme, Otsuka Pharmaceutical. K. Henriksson: Employment; Significant; AstraZeneca. M.P. Hermans: Honoraria; Modest; Abbott, Amgen, AstraZeneca, Bristol-Myers Squibb, Boerhinger Ingelheim, Eli Lilly, GlaxoSmithKline, LifeScan, Menarini, Novartis, NovoNordisk, Pfizer, Sanofi-Aventis, Takeda. Consultant/Advisory Board; Modest; Abbott, GlaxoSmithKline, Novartis, Eli Lilly, Sanofi, Takeda.
- © 2014 by American Heart Association, Inc.